A large number of active ingredients can benefit from liposomal packaging. Many approved active ingredients cause severe side effects when used systemically because they are not targeted, or they have to be dosed too high because they only circulate in the body for a short time. A liposomal formulation opens up new possibilities here. InnoMedica's technology platform can be used both for clinically established active ingredients and for new, customized substances such as RNA or proteins. Through targeted design adjustments, InnoMedica's liposomal nanoparticle can be specifically adapted to the properties of the disease and the affected tissue, as well as the transported active ingredient. There are virtually no limits to InnoMedica's product pipeline.
In oncology, InnoMedica is further developing the proven chemotherapy doxorubicin with TLD-1. In addition to the indication of breast cancer, the preparation for market approval focuses mainly on the rare cancer of soft tissue sarcoma (STS). InnoMedica's liposomal formulation is designed to prevent the known active ingredient's otherwise occurring and often intolerable side effects. InnoMedica's neurology product TLN-1, which is in clinical development, is designed to counteract neurodegenerative diseases such as Parkinson's. InnoMedica's transport system enables the blood-brain barrier to be crossed, thus delivering the active ingredient GM1 to the brain. InnoMedica is also developing a product to label tumors for more precise surgical removal (TLTrace) and is working on further developing another widely used chemotherapy, docetaxel (TLTaxel).
Research
Preclinical
Clinical
The nanocarrier of InnoMedica's oncology product transports the already approved, highly effective active ingredient doxorubicin and is designed to prevent serious, sometimes irreversible side effects of this chemotherapy. The intelligent surface coating of the liposomal nanoparticle ensures minimal interaction of the active ingredient with healthy tissue. The longer blood circulation time protects the excretory organs as they have more time for the degradation process. As the liposomal nanocarrier of the preparation is particularly small, targeted penetration of the tumor tissue and thus a high level of drug accumulation in the tumor is ensured.
Thanks to the unique composition of the nanocarrier for InnoMedica's neurology product, the active ingredient GM1 ganglioside that is integrated into the membrane can cross the blood-brain barrier and unfold its neuroprotective and neuroregenerative effect in the brain. GM1 ganglioside is an important component of nerve cells and plays a central role in neuronal development, information transmission and storage, in repair mechanisms and in the release of neurotrophins (messenger substances that are essential for the survival and regeneration of nerve cells). As InnoMedica's nanocarrier crosses the blood-brain barrier, the brain is supplied with more GM1 to protect the nerve cells. As it is an endogenous substance, it is also well tolerated.
